EPS for AmpliPhi Biosciences Corporation (APHB) Expected At $-0.36

March 18, 2018 - By Vivian Park

 EPS for AmpliPhi Biosciences Corporation (APHB) Expected At $ 0.36

Analysts expect AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) to report $-0.36 EPS on March, 26.They anticipate $2.84 EPS change or 88.75 % from last quarter’s $-3.2 EPS. After having $-0.09 EPS previously, AmpliPhi Biosciences Corporation’s analysts see 300.00 % EPS growth. The stock increased 1.95% or $0.03 during the last trading session, reaching $1.57. About 392,069 shares traded. AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) has declined 94.86% since March 18, 2017 and is downtrending. It has underperformed by 111.56% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $14.91 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.